RENILLA LUCIFERASE AS A REPORTER TO ASSESS SARS-CoV mRNA TRANSCRIPTION REGULATION AND EFFICACY OF ANTI-SARS-CoV AGENTS

Rhonda S. Roberts, Boyd L. Yount, Amy C. Sims, Susan Baker, and Ralph S. Baric*

1. INTRODUCTION

SARS coronavirus (SARS-CoV) is the etiologic agent responsible for the pandemic of SARS.1 We have developed a reverse genetics model to characterize the pathways of replication and pathogenesis of this virus.2 Renilla Luciferase was used as a reporter gene and inserted into the backbone of the infectious clone of SARS-CoV to replace ORF 7a/b (SARS wt-Luc), which is believed to have apoptotic effects on host cells. Subsequently, to measure the impact of the transcription regulatory sequence (TRS) on gene expression, either two or three mutations were introduced into the ORF 7a/b TRS hexanucleotide site of the luciferase cassette; SARS 2mut-Luc and SARS 3mut-Luc, respectively (Figure 1).

Figure 1. Structure of SARS wt-Luc and introduction of mutations into the TRS site to create the SARS 2mut-Luc and SARS 3mut-Luc viruses.

*Rhonda S. Roberts, Boyd L. Yount, Amy C. Sims, Ralph S. Baric, University of North Carolina, Chapel Hill, North Carolina 27599. Susan Baker, Loyola University Medical Center, Maywood, Illinois 60153.
2. RESULTS AND DISCUSSION

Recombinant viruses with all three Luciferase constructs were isolated and shown to stably maintain the *Renilla* Luciferase gene and to express subgenomic mRNA encoding luciferase. The growth kinetics of all three constructs was similar, suggesting that the TRS mutations did not affect the efficacy of virus replication. However, Western blot analysis detected Luciferase protein in the SARS wt-Luc construct but did not detect the expression of any Luciferase protein in cells infected with the 2mut and 3mut recombinant viruses. Likewise, Northern blot analysis exhibited a severely decreased amount of subgenomic Luciferase mRNA in cells infected with the two mutant constructs (data not shown). Combined, these results effectively demonstrate that the TRS mutations attenuate the virus’ ability to efficiently produce or translate subgenomic mRNA. This analysis was verified utilizing the Dual-Glo Luciferase Assay System kit (Promega) to detect Luciferase enzyme activity. The Luciferase expression, measured in relative light units (RLU), decreased from almost 1 log to approximately 1.5 logs in cells infected with the 2mut and 3mut constructs, respectively (Figure 2).

Sequence analysis of the mutant viruses suggested that the reduced Luciferase expression was due to a mechanism used to bypass the mutations in the TRS region. There were various noncanonical leader body-junctions identified surrounding the TRS region in the subgenomic sequence in the two mutant constructs. Replicase slippage and the usage of noncanonical TRS-like junctions allowed for low level subgenomic transcription and expression of Luciferase.

The recombinant SARS wt-Luc virus was also used to measure the efficacy of putative anti-SARS agents. Four various interferon (IFN) treatments were tested in their ability to protect host cells against SARS infection: IFN-α2, IFN-β, IFN-γ, and a mixture of IFN-β plus IFN-γ. CaCo2 cells were seeded at an approximate concentration of

![Figure 2](image-url)
RENILLA LUCIFERASE AS A REPORTER TO CHARACTERIZE SARS-CoV

2 * 10^5 cells/well on a 96-well plate 24 hours prior to infection. At 8 hours prior to infection, 0–200 international units (U) of the appropriate IFN treatment was added to whole media. Cells were infected with SARS wt-Luc at a multiplicity of infection (MOI) of 0.5 and allowed to incubate at room temperature for 1 hour. Luciferase expression was measured at various time points for 24 hours postinfection (HPI). While all IFN treatment effectively inhibited SARS infection by at least 2 logs, the synergistic effect of IFN-β/IFN-γ had the most extreme effect at 200 U, decreasing luciferase activity by more than 3 logs or more than 98% (Figure 3).

In addition to IFN treatment, synthetic chemical compounds were developed to inhibit MPro binding; 0309, 0310, 0312, and 0313. Vero E6 cells were seeded approximately 24 hours prior to infection as described above. They were infected with SARS wt-Luc at a MOI of 0.5 and allowed to incubate for 1 hour at room temperature. Subsequently, 150 µl of whole media with 100 µM of the appropriate drug was added. Luciferase expression was assessed via the luciferase bioassay at various time points up to 40 HPI. Each drug decreased luciferase expression by at least 40% (Figure 4). Anti-SARS agent 0310 was then used in subsequent effective dose studies. Vero E6 cells were initially treated in the same manner except, after the 1 hour infection period, 150 µl media with 0310 diluted at various concentrations, ranging from 6.25 µM to 200 µM, was added to each well. Again, the Luciferase expression was measured until 31 HPI. 0310 exhibited a small dose-response with 6.25 µM decreasing Luciferase activity 1 log and increasing concentrations thereafter showing enhanced activity, with an almost 2 log reduction at a concentration of 0310 of 200 µM (data not shown).

We demonstrate that SARS wt-Luc is a viable virus that allows for studies of the effect of subgenomic manipulation on virus efficacy, both in replication and subgenomic

![Figure 3. Luciferase expression in SARS wt-Luc infected CaCo2 cells treated with interferons at 200 U.](image-url)
production. In utilizing this virus, we not only have a sensitive way to evaluate virus growth using Luciferase expression as a proxy, but we also show the importance of the TRS region on subgenomic mRNA production and/or translation.

Our approach offers an alternative to plaque assay analysis in testing the efficiency of anti-SARS agents. The Dual-Glo Luciferase Assay System (Promega) in conjunction with our SARS wt-Luc virus provides a rapid, extremely sensitive, accurate, and high-through-put screening method.

3. ACKNOWLEDGMENTS

This research was funded by NIH grants P01 AI059443 and AI059136.

4. REFERENCES

1. T. G. Ksiazek, et al., A novel coronavirus associated with severe acute respiratory syndrome, *N. Engl. J. Med.* **348**, 1953-1966 (2003).

2. B. Yount, et al., Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus, *Proc. Natl. Acad. Sci. USA* **100**, 12995-13000 (2003).